BASEL, Switzerland, Sept. 28 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) discloses its list of licenses.
NEURO # 1
SymPath(R)
TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME, DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE STATES AND ANXIOUS DISORDERS.
NEURO # 2
AXIS(TM)
TO QUANTITATIVELY AND DIRECTLY EVALUATE THE HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.
NEURO # 3
TETRIC(TM)
TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE & INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.
NEURO #4 and #5
ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE OUT THE CLINICAL PREDOMINENCE
NEURO # 6
TRYPTYR
TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.
NEURO #7
DIVAN
TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.
NEURO # 8
GACHA
TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE CELLULAR ENERGETIC CAPACITY.
NEURO # 9
FREERAD
TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN REGARDS TO THE AXIS ACTIVITY.
NEURO # 10
MAOS
TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND THERAPEUTIC APPROACHES.
NEURO # 11
NEURENDOM
TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
NEURO # 12
NEURENDOF
TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
SOURCE Neuro-Biotech Corp.
Share this article